homepage-top-section

The approval follows positive results from the Phase I/II GO29781 study, which demonstrated that Lunsumio SC has pharmacokinetic non-inferiority to intravenous (IV) administration. No unexpected safety issues were

The acquisition brings Halda’s lead candidate, HLD-0915, a clinical-stage treatment for prostate cancer, into Johnson & Johnson’s oncology portfolio. This once-daily therapy presents an opportunity to enhance patient

The inhaler administers three active ingredients through a single device, known as single inhaler triple therapy (SITT), which has already received approval in nearly 50 countries. It combines

Orca-T is being assessed to treat hematological malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML), and acute lymphoblastic leukaemia (ALL). The FDA has granted priority review, with

The approval applies to individuals with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes or non-carriers. Kisunla, administered as a monthly infusion, is already available in several

The launch follows approval from the US Food and Drug Administration (FDA). Iron sucrose is a key treatment for iron deficiency anaemia, affecting around five million people in

The drug is indicated for adults with mild cognitive impairment or mild dementia, who are non-carriers or heterozygotes of apolipoprotein E ε4 (ApoE ε4) with confirmed amyloid pathology.

Genentech will obtain rights for OMass’ preclinical oral small molecule programme for IBD, as part of the agreement. OMass Therapeutics CEO Ros Deegan said: “Using our OdyssION platform,

This new dosing option enables patients with mild cognitive impairment or mild dementia to receive treatment at home, following an initial intravenous (IV) administration. Leqembi Iqlik, administered through